摘要
生物技术的发展,催生了新一代以嵌合型抗原受体T(CART)细胞为代表的细胞治疗技术。CART细胞治疗难治、复发性儿童白血病取得了令人惊喜的初步疗效,为这一临床难题开辟了新的治疗思路。但其临床应用的长期疗效及安全性尚有待进一步观察。
The development of biotechnology has spawned a new generation of cell therapy represented by chimeric antigen receptor gene modified T cells（CART）. The treatment for refractory and relapsed childhood leukemia is a formidable clinical problem. CART cell therapy has preliminary improved outcome,which is initiating a new idea for the treatment.However,the long-term efficacy and safety of CART cell therapy needs to be further observed.
出处
《中国实用儿科杂志》
CSCD
北大核心
2016年第4期274-277,共4页
Chinese Journal of Practical Pediatrics
关键词
嵌合型抗原受体T细胞
细胞治疗
安全性
chimeric antigen receptor gene modified T cell（CART）
cell therapy
safety
